Monitoring the Impact of the Human Papillomavirus (HPV) Vaccine: The National Perspective


HPV is a sexually transmitted infection and the primary cause of genital warts and anogenital cancers. A new prophylactic HPV vaccine is recommended for routine use in females ages 11-12 years with catch-up for 13-26 year olds. Evaluating the impact of the vaccine requires monitoring several biologic and behavioral endpoints.

Objectives of Symposium:

Provide an overview of national efforts to develop sustainable systems to monitor the impact of HPV vaccine on disease outcomes and screening behaviors.

Implications for Programs, Policy, and/or Research:

Information presented will highlight national efforts toward a coordinated approach to HPV impact monitoring and the role of STD programs therein.

Tuesday, March 11, 2008: 10:00 AM-11:45 AM
Northwest 2
10:05 AM
Monitoring Genital Warts in STD Clinics
Lori M. Newman, MD, Centers for Disease Control and Prevention
10:45 AM
Use of VSD to Monitor HPV-related Outcomes and HPV Types
Eileen F. Dunne, MD, MPH, Centers for Disease Control and Prevention
See more of: Symposium